Stock Market News
Oxford BioDynamics presents ALS biomarker data at CNS Summit
AIM-quoted biotechnology firm Oxford BioDynamics has presented its latest biomarker data in a plenary talk at the sixth World CNS Summit in Boston, Massachusetts after it identified non-invasive biomarkers for the diagnosis and prognosis of neurodegenerative and psychiatric disorders.
Oxford Bio demonstrated that EpiSwitch, its new biomarker, saw results in patients suffering from ALS, a progressive neurodegenerative disorder with no single diagnostic test, that defined "actionable stratifications for individual patients on the basis of high-resolution detection of chromosome conformations and regulatory genome 3D architecture."
Additional applications and examples of chromosome conformation stratifications were also presented and discussed at the CNS Summit for the extended range of indications of neurodegeneration, psychiatric disorders and related autoimmune and inflammatory conditions, including multiple sclerosis, lupus, treatment-resistant depression, autism and post-traumatic stress disorder.
Dr Alexandre Akoulitchev, chief scientific officer of Oxford BioDynamics, said, "We believe that delivering non-invasive prognostic biomarkers for ALS and building the insights into sub-typing of ALS is highly important. We aim to provide practical solutions that could benefit each and every individual patient that undergoes prognostic evaluation as early as possible and then receives one of the few available treatments."
"Earlier reports and the latest published validations of EpiSwitch stratifications from diagnostic, prognostic and biomarkers for response to treatment, gives OBD a unique opportunity to make a highly valuable contribution to improved patient care, clinical decisions and evidence of efficacy in drug treatments," he concluded.
As of 1000 GMT, shares had lost 1.21% to 163.00p.
Oxford Bio demonstrated that EpiSwitch, its new biomarker, saw results in patients suffering from ALS, a progressive neurodegenerative disorder with no single diagnostic test, that defined "actionable stratifications for individual patients on the basis of high-resolution detection of chromosome conformations and regulatory genome 3D architecture."
Additional applications and examples of chromosome conformation stratifications were also presented and discussed at the CNS Summit for the extended range of indications of neurodegeneration, psychiatric disorders and related autoimmune and inflammatory conditions, including multiple sclerosis, lupus, treatment-resistant depression, autism and post-traumatic stress disorder.
Dr Alexandre Akoulitchev, chief scientific officer of Oxford BioDynamics, said, "We believe that delivering non-invasive prognostic biomarkers for ALS and building the insights into sub-typing of ALS is highly important. We aim to provide practical solutions that could benefit each and every individual patient that undergoes prognostic evaluation as early as possible and then receives one of the few available treatments."
"Earlier reports and the latest published validations of EpiSwitch stratifications from diagnostic, prognostic and biomarkers for response to treatment, gives OBD a unique opportunity to make a highly valuable contribution to improved patient care, clinical decisions and evidence of efficacy in drug treatments," he concluded.
As of 1000 GMT, shares had lost 1.21% to 163.00p.
Related share prices |
---|
Oxford Biodynamics (OBD) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price